Back

Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?

European Heart Journal

9 April 2019
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY HYPERTENSION OTHER PREVENTIVE CARDIOLOGY Risk Factors and Prevention Pharmacology and Pharmacotherapy

Contributors

Franz H Messerli
Franz H Messerli

Author

Lucerne Cantonal Hospital Luzern , Switzerland

Michel Burnier
Michel Burnier

Author

You may be interested in
thumbnail
Congress Presentation
Meta-analysis assessing cardiovascular outcomes with febuxostat versus allopurinol for patients with gout
27 August 2021
thumbnail
Congress Session
Novel mechanisms for insights into atherosclerosis
26 August 2023
thumbnail
Congress Presentation
Relationship between morning blood pressure increasing, left ventricle dysfunction and uric acid level in hypertensive patients
29 June 2021
thumbnail
Congress Presentation
J-shaped association between serum uric acid levels and chronic kidney disease: a cross-sectional study using large health examination data
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources